Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Gaetan des Guetz"'
Autor:
Gaetan Des Guetz, Bernard Uzzan, Thierry Bouillet, Patrick Nicolas, Kader Chouahnia, Laurent Zelek, Jean-François Morere
Publikováno v:
Gastroenterology Research and Practice, Vol 2013 (2013)
Background. Physical activity (PA) reduces incidence of colorectal cancer (CRC). Its influence on cancer-specific (CSS) and overall survival (OS) is controversial. Methods. We performed a literature-based meta-analysis (MA) of observational studies,
Externí odkaz:
https://doaj.org/article/65a07caa10ca42b18d6e2168ebd28779
Autor:
Gaetan des Guetz, Alain Chapelier, Véronique Mosseri, Thierry Dorval, Bernard Asselain, Pierre Pouillart
Publikováno v:
Sarcoma, Vol 2009 (2009)
Purpose. An analysis of the clinicopathologic features and treatment of patients was performed to guide evaluation and management of postirradiation sarcoma. Patients and Methods. Between 1994 and 2001, 25 patients with postirradiation sarcoma were t
Externí odkaz:
https://doaj.org/article/64d1b2e7f23d45be80c2a53054f3b570
Publikováno v:
Drugs & Aging. 37:747-754
The impact of aging on the effectiveness of immune checkpoint inhibitors (ICIs) remains controversial, and little is known on the subject in adults aged ≥ 75 years. The objective of this comprehensive meta-analysis was to assess the efficacy of ICI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce25a9ff816a1be8f8ce4b70cee2a912
https://doi.org/10.1007/s40266-020-00788-5
https://doi.org/10.1007/s40266-020-00788-5
Autor:
Boris Duchemann, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Thierry Landre, Christos Chouaid
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:3333-3339
Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition of a vascular endothelial growth factor (VEGF) inhibitor (anti-VEGF) in comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892b81f13f8f85c210aee3a85604d9be
https://doi.org/10.1007/s00432-020-03311-w
https://doi.org/10.1007/s00432-020-03311-w
Publikováno v:
Journal of Women's Health and Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60f95ae98d317ff49e762d5b9b07876d
https://doi.org/10.26502/fjwhd.2644-28840086
https://doi.org/10.26502/fjwhd.2644-28840086
Publikováno v:
Cancers, Vol 13, Iss 6035, p 6035 (2021)
Cancers
Cancers
Simple Summary Neoadjuvant fluoropyrimidine (5FU or capecitabine)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Our Meta-analysis showed that the combining oxaliplatin with capecitab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad297153770a5b8cd42a5d4b2527775
https://www.mdpi.com/2072-6694/13/23/6035
https://www.mdpi.com/2072-6694/13/23/6035
Autor:
Alain Vergnenegre, Gaetan Des Guetz, Thierry Landre, Cherifa Taleb, Kader Chouahnia, Christos Chouaid
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:441-448
Single-agent anti-PD-1/PD-L1 clinical efficacy against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be08aacc9dad36ac07a8ba3e3b636b7b
https://doi.org/10.1007/s00432-019-03070-3
https://doi.org/10.1007/s00432-019-03070-3
Autor:
Isabelle Trouilloud, Nabil Baba-Hamed, Marie-Pierre Galais, David Tougeron, Romain Coriat, Jean-Philippe Metges, Olivier Bouché, Jean-Marc Phelip, Lola-Jade Palmieri, Laurent Mineur, Benoit Rousseau, Victoire Granger, Lea Saban-Roche, Pierre Michel, Julie Henriques, Jean-Marc Gornet, Emilie Soularue, Astrid Lièvre, Denis Smith, Dewi Vernery, Stéphane Obled, Gael Goujon, Christophe Locher, Anne-Laure Bignon-Bretagne, Gaetan Des Guetz, Sylvain Manfredi, Solene Doat, Bruno Buecher, Marie Dior, Carole Vitellius, Simon Pernot
Publikováno v:
Oncologist
Oncologist, AlphaMed Press, 2020, 25 (2), ⟨10.1634/theoncologist.2019-0328⟩
The Oncologist
Oncologist, AlphaMed Press, 2020, 25 (2), ⟨10.1634/theoncologist.2019-0328⟩
The Oncologist
Background Patients with RAS wild‐type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti‐epidermal growth factor receptor (EGFR) combined with first‐line, 5‐fluorouracil‐based chemotherapy. Wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c84650cfe1be695e638734a84b0ce18
https://doi.org/10.1634/theoncologist.2019-0328
https://doi.org/10.1634/theoncologist.2019-0328
Autor:
Jean-Baptiste Assié, Christos Chouaid, Gaetan Des Guetz, Boris Duchemann, Kader Chouahnia, Thierry Landre
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Introduction: Platin-based chemotherapy (CT) has long been the first-line standard-of-care for patients with extensive-stage small-cell lung cancer (ES–SCLC). Adding immune-checkpoint inhibitor(s) to CT (ICI+CT) in this setting is an option of inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a20b12f9f39489c8c8f2eb8c33184dc
https://doaj.org/article/98a3806216fe4bb49fd3d4807ffea523
https://doaj.org/article/98a3806216fe4bb49fd3d4807ffea523
Background The impact of ageing on Immune Checkpoint Inhibitors (ICIs) effectiveness remains controversial. However, data from clinical studies do not show any difference between patients over 65 years and those under 65 years. We focused our study o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::408df0479faaf86457b6f9161053dada
https://doi.org/10.21203/rs.3.rs-26423/v1
https://doi.org/10.21203/rs.3.rs-26423/v1
